XenoTech rolls out CryostaX offering for drug developers
Pooled human hepatocytes are a commonly used test system in many drug discovery and development programmes, primarily in the assessment of metabolic clearance of a particular drug candidate.
Like other hepatocyte products on the market CryostaX is derived from a limited pool of samples, 10 to be specific, that are selected to provide developers with a population sample that is representative of the population for which the drug is intended.
What differs about CryostaX, according to the US contract research organisation (CRO), is a unique processing technology that enables the cells to be pooled after only one freeze cycle.
The use of just one freezing step means that the cells retain more of the enzymatic activity of “fresh” hepatocytes and therefore provide a more accurate and representative model of drug metabolism and elimination in vivo.
XenoTech also guarantees that each CryostaX vial contains a minimum of 5m hepatocyte and that cells from each of the ten donors are significantly represented in the final preparation.
Company CSO Andrew Parkinson said that: "CryostaX is an example of our continuous commitment to provide the best products to advance in vitro drug development research.”
He added that: “CryostaX allows for future customization of pooled human hepatocytes for the in-depth pursuit of safe drug candidates."
